image
Healthcare - Biotechnology - NASDAQ - US
$ 71.395
-1.5 %
$ 3.27 B
Market Cap
-15.74
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one SLNO stock under the worst case scenario is HIDDEN Compared to the current market price of 71.4 USD, Soleno Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one SLNO stock under the base case scenario is HIDDEN Compared to the current market price of 71.4 USD, Soleno Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one SLNO stock under the best case scenario is HIDDEN Compared to the current market price of 71.4 USD, Soleno Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SLNO

image
$75.0$75.0$70.0$70.0$65.0$65.0$60.0$60.0$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
0 REVENUE
0.00%
0 OPERATING INCOME
100.00%
-176 M NET INCOME
-351.04%
-69.1 M OPERATING CASH FLOW
-177.05%
-226 M INVESTING CASH FLOW
0.00%
213 M FINANCING CASH FLOW
18.33%
0 REVENUE
0.00%
-59.1 M OPERATING INCOME
26.30%
-56 M NET INCOME
26.93%
-24 M OPERATING CASH FLOW
-60.73%
6.44 M INVESTING CASH FLOW
59.48%
57.1 M FINANCING CASH FLOW
2408.26%
Balance Sheet Soleno Therapeutics, Inc.
image
Current Assets 294 M
Cash & Short-Term Investments 291 M
Receivables 0
Other Current Assets 2.45 M
Non-Current Assets 37.1 M
Long-Term Investments 0
PP&E 2.98 M
Other Non-Current Assets 34.1 M
88.05 %10.30 %Total Assets$331.0m
Current Liabilities 18.7 M
Accounts Payable 8.88 M
Short-Term Debt 526 K
Other Current Liabilities 9.34 M
Non-Current Liabilities 67.1 M
Long-Term Debt 2.47 M
Other Non-Current Liabilities 64.6 M
10.34 %10.88 %2.88 %75.29 %Total Liabilities$85.9m
EFFICIENCY
Earnings Waterfall Soleno Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 188 M
Operating Income 0
Other Expenses 176 M
Net Income -176 M
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)(200m)(200m)000(188m)0(176m)(176m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-71.74% ROE
-71.74%
-53.13% ROA
-53.13%
0.00% ROIC
0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Soleno Therapeutics, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -176 M
Depreciation & Amortization 1.99 M
Capital Expenditures -218 K
Stock-Based Compensation 100 M
Change in Working Capital 6.02 M
Others -863 K
Free Cash Flow -69.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Soleno Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for SLNO of $80.1 , with forecasts ranging from a low of $59 to a high of $105 .
SLNO Lowest Price Target Wall Street Target
59 USD -17.36%
SLNO Average Price Target Wall Street Target
80.1 USD 12.21%
SLNO Highest Price Target Wall Street Target
105 USD 47.07%
Price
Max Price Target
Min Price Target
Average Price Target
1101101001009090808070706060505040403030Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Soleno Therapeutics, Inc.
image
Sold
0-3 MONTHS
200 M USD 8
3-6 MONTHS
1.69 M USD 4
6-9 MONTHS
65.6 M USD 5
9-12 MONTHS
53 M USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Soleno Therapeutics Announces VYKAT(TM) XR Launch REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the U.S. commercial availability of VYKAT™ XR (diazoxide choline) extended-release tablets, the company's treatment for hyperphagia in patients four years of age and older with Prader-Willi syndrome (PWS), which was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025. globenewswire.com - 2 weeks ago
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients. zacks.com - 1 month ago
Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder The U.S. Food and Drug Administration (FDA) on Wednesday approved Soleno Therapeutics, Inc.'s SLNO Vykat XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS). benzinga.com - 1 month ago
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26 th , at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS). globenewswire.com - 1 month ago
Soleno Therapeutics to Participate in Upcoming February Investor Conferences REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February: globenewswire.com - 3 months ago
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it has entered into a loan and security agreement with Oxford Finance LLC and its affiliates (Oxford) for up to $200 million. globenewswire.com - 4 months ago
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time. globenewswire.com - 5 months ago
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome REDWOOD CITY, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. globenewswire.com - 5 months ago
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024 REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will be presenting data from its DCCR clinical development program for the treatment of Prader-Willi syndrome (PWS) at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2024, being held November 16-18, 2024 in Liverpool, UK. globenewswire.com - 5 months ago
Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments Soleno Therapeutics' DCCR shows promising results in reducing hyperphagia in PWS patients. I believe its FDA approval is likely by December 27, 2024. DCCR could become the first approved treatment for PWS hyperphagia, addressing a significant unmet medical need. DCCR's unique mechanism targets PWS hyperphagia while preserving lean mass. This potentially extends its use beyond PWS to weight loss, enhancing SLNO's market prospects. seekingalpha.com - 6 months ago
SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA Soleno stock gains as the FDA says no advisory committee meeting is required for the DCCR NDA at present to treat hyperphagia associated with PWS. zacks.com - 6 months ago
Recent Price Trend in Soleno Therapeutics (SLNO) is Your Friend, Here's Why If you are looking for stocks that are well positioned to maintain their recent uptrend, Soleno Therapeutics (SLNO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. zacks.com - 6 months ago
8. Profile Summary

Soleno Therapeutics, Inc. SLNO

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 3.27 B
Dividend Yield 0.00%
Description Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Contact 203 Redwood Shores Parkway, Redwood City, CA, 94065 https://soleno.life
IPO Date Nov. 13, 2014
Employees 92
Officers Mr. Jesse Schumaker General Counsel Dr. Michael Huang M.D. Senior Vice President of Clinical Development Dr. Mitchell Nagao M.B.A., Pharm.D. Senior Vice President of Medical Affairs Mr. James H. MacKaness Chief Financial Officer & Compliance Officer Ms. Patricia C. Hirano M.P.H. Senior Vice President of Regulatory Affairs Ms. Lauren Budesheim Vice President of People Dr. Neil M. Cowen M.B.A., Ph.D. Senior Vice President of Drug Development Ms. Meredith Manning M.B.A. Chief Commercial Officer Ms. Kristen Yen M.S. Senior Vice President of Clinical Operations Dr. Anish Bhatnagar M.D. President, Chief Executive Officer, Chief Operating Officer & Director